Vigilant Biosciences has previously announced four additional distribution agreements in place throughout Europe, Asia, and Australia. The three new agreements further expand Vigilant Biosciences’ reach throughout Europe and the Middle East and support the company’s goal to deliver accurate and cost-effective tools for clinicians involved in the diagnosis and treatment of oral cancer.
The new distribution partners announced include Dentamed for the distribution of the OncAlert Oral Cancer System to the dental markets in Czech Republic and Slovakia; S.I.R.A.M. Ltd. for distribution of the OncAlert Oral Cancer System to the medical and dental markets in Israel; and the Diamedica OU Group for distribution of the OncAlert Oral Cancer System to the medical and dental markets in the Baltic region, which includes Estonia, Latvia and Lithuania.
As part of the new multiyear deals the OncAlert Oral Cancer System will be available to customers in these regions starting in the first quarter of 2016.
“We are pleased to announce that we are continuing to expand the distribution channels for the OncAlert Oral Cancer System throughout Europe and the Middle East with these three new agreements,” said Matthew H.J. Kim, founder, chairman, and CEO of Vigilant Biosciences Inc. “Through these partnerships, we will be able to provide simple, accurate and cost-effective solutions as an aid in the diagnosis of oral cancer in patients, which will result in earlier detection and intervention.”
Source: Vigilant Biosciences press release 17 November 2015